Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page
- CheckyesterdayChange DetectedThe page displays the completed Phase 2 pancreatic cancer study record, including its treatment regimen, eligibility criteria, outcome measures, study locations, and supporting documents.SummaryDifference70%

- Check8 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA notice about the NIH website terminology transition appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check36 days agoChange DetectedThe site footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check50 days agoChange Detected- Core study documents (Statistical Analysis Plan; Study Protocol) were removed from the Study Documents section, reducing access to essential methodological and regulatory details. - The page now displays a 403 Forbidden error, indicating the page is currently inaccessible.SummaryDifference19%

- Check57 days agoChange DetectedRevision: v3.7.0 has been added, replacing the previous v3.6.6, indicating an update to the page's version tag in the metadata.SummaryDifference0.0%

Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.